Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion

4 Feb 2021

Abstract excerpt

Among the various types of breast cancer, the luminal B subtype is the most common in young women, and ESR1-CCDC170 (E:C) fusion is the most frequent oncogenic fusion driver of the luminal B subtype. Nevertheless, treatments targeting E:C fusion has not been well established yet. Hence, the aim of this study is to investigate potential therapies targeting E:C fusion based on systematic bioinformatical analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to PARP inhibition in cancer therapy
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33557149
DOI: 10.3390/jcm10040582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 FusionPMID 33557149Read ↗

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistanceSemantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

<scp>Fusion‐associated</scp>carcinomas of the breast: Diagnostic, prognostic, and therapeutic significanceSemantic proximity Read ↗

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Semantic proximity Read ↗

Fusion Genes in Breast Cancer.Semantic proximity Read ↗

Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.Semantic proximity Read ↗

OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicineSemantic proximity Read ↗

The Prognostic and Predictive Value of ESR1 Fusion Gene Transcripts in Primary Breast CancerSemantic proximity Read ↗

OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine.Semantic proximity Read ↗

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.Semantic proximity Read ↗

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSemantic proximity Read ↗

<i>ESR1</i> fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.